Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

By K. Miller, N. Foster, R. Beck, R. Bergenstal, Stephanie N. DuBose, L. Dimeglio, David M. Maahs, W. Tamborlane. Diabetes Care, 2015

1,200 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/f8f903d099156bb13281ff05a9488417a39c657b

Citations in the corpus

• An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes (2019, neutral): “Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”